Despite the success of targeted therapies in cancer treatment, therapy-induced resistance
remains a major obstacle to a complete cure. Tumor cells evade treatments and relapse via …

Immune checkpoint inhibitors (ICIs) are a group of drugs designed to improve the
therapeutic effects on various types of malignant tumors. Irrespective of monotherapy or …

Objective The objective was to review the pharmacology, efficacy, and safety of
atezolizumab (Tecentriq) for the treatment of adult and pediatric patients aged 2 years and …

Programmed cell death protein-1 (PD-1) and its ligand (programmed death ligand 1, PD-L1)
inhibitors, as the rising stars of immunotherapy, have been widely used in clinical practice …

Immune checkpoint inhibitors (ICIs) have become the cornerstone in treating many solid and
hematological cancers. The ICIs, including anti-cytotoxic T lymphocyte-associated protein 4 …

Introduction Hepatocellular carcinoma (HCC) is the fifth malignancy in terms of frequency
and the fourth malignancy in terms of cancer-related death worldwide. Systemic therapy of …

Covariate modeling is an important opportunity for pharmacometrics to influence decision
making in drug development. The stepwise covariate model (SCM) building procedure is the …

Hepatocellular carcinoma (HCC) is one of the most common leading causes of cancer death
worldwide. As most patients are diagnosed with advanced disease, systemic therapy …

Introduction: The treatment of unresectable hepatocellular carcinoma (HCC) has radically
changed after the approval of the combination of atezolizumab plus bevacizumab as first …

Cancer stem cells (CSCs) may be dedifferentiated somatic cells following oncogenic
processes, representing a subpopulation of cells able to promote tumor growth with their …